Listen
VIPERFAV (fragments F(ab’)2 of European viper antivenom equine immunoglobulin (Vipera aspis, Vipera berus, Vipera ammodytes))
Opinions on drugs -
Posted on
Jan 09 2025
Reason for request
Initial inclusion
Summary of opinion
Favourable opinion for reimbursement in the treatment of envenomation (grade II or III) by European vipers (Vipera aspis, Vipera berus, Vipera ammodytes), in patients with rapidly spreading oedema and/or systemic signs: vomiting, diarrhoea, abdominal pain and hypotension.
No clinical added value of the new concentrate for solution for infusion form compared to the forms already available.
Clinical Benefit
| Substantial |
The clinical benefit of VIPERFAV is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the form already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
